Current Issues of Pharmacy and Medical Sciences

Immunomodulatory and anti-inflammatory properties of macrolides

Curr Issues Pharm Med Sci., Vol. 27, No. 1, Pages 61-64

Magdalena Bulska, Daria Orszulak-Michalak

Chair and Department of Biopharmacy, Faculty of Pharmacy, Medical Univeristy of Lodz, ul. Muszyńskiego 1, 90-151 Łódź, Poland

DOI: 10.2478/cipms-2014-0015



Macrolides are a group of antibiotics whose activity is ascribable to the presence of the macrolide ring, to which one or more deoxy sugars may be attached. Two properties are inherent in this group of antibiotics, the immunomodulatory and the anti-inflammatory actions, ensuring great efficacy in a wide spectrum of infections. Macrolides demonstrate several immunomodulatory activities both in vitro and in vivo. They can down-regulate prolonged inflammation, increase mucus clearance, prevent the formation of bacterial biofilm and either enhance or reduce activation of the immune system. According to given properties and exceptional effects on bacterial phatogens, the macrolide antimicrobial agents have been found to serve a unique role in the management of chronic airway disorders, including diffuse panbronchiolitis, cystic fibrosis and chronic obstructive pulmonary disease. Use of macrolides can result in clinical improvement in patients with severe, chronic inflammatory airway diseases, improving their spirometry indicators, gas exchange and overall quality of life.


Full Text


antibiotics, immunomodulation, inflammation, macrolides


  1. Altenburg J. et al.: Immunomodulatory effects of macrolide antibio­tic-part 1: biological mechanisms. Respiration, 81, 67, 2011.
  2. Cazalias J., Tanabe S., Gagnon G.: Tetracyclines and chemically modified tetracycline-3 (CMT-3) modulate cytokine secretion by lipopolysaccharide-stimulated whole blood. Inflammation, 32, 130, 2009.
  3. Culic O., Erakovic V., Parnham M.J.: Anti-inflammatory effects of macrolide antibiotics. Eur. J. Pharmacol., 429, 209, 2001.
  4. Friedlander A.L., Albert R.K.: Chronic macrolide therapy in inflam­matory airway diseases. Chest, 138, 1202, 2010.
  5. Hodge S., Hodge G., Jersmann H.: Azithromycin improves macro­phage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 178, 139, 2008.
  6. Itkin I.H., Menzel M.L.: The use of macrolide antibiotic substances in the treatment of astma. J. Allergy, 45, 146, 1970.
  7. Kudoh S., Azuma A., Yamamoto M.: Improvement of survival in patients with diffuse panbrochiolitis treated with low-dose eryth­romycin. Am. J. Respir. Crit. Care Med., 157, 1829, 1998.
  8. Martinez F., Curtis J., Albert R.: Role of macrolide therapy in chronic obstructive pulmonary disease. Interantional Journal of COPD, 3, 331, 2008.
  9. Rubin B.K., Henke M.O.: Immunomodulatory activity and effecti­veness of macrolides in chronic airway disease. Chest, 125, 70, 2004.
  10. Targowski T., Jahnz-Różyk K.: Immunomodulatory properties of macrolides. Pol. Merk. Lek., 149, 408, 2008.
  11. Ungureanu V.: Macrolides, lincosamides, streptogramines (MLS): mechanisms of action and resistance. Bacteriol Virusol Parazitol Epidemiol., 55, 131, 2010.
  12. Zarogoulidis P. et al.: Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practise in respiratory diseases. Eur. J. Clin. Pharmacol., 68, 479, 2012.


April 2020

Mon Tue Wed Thu Fri Sat Sun
    01 02 03 04 05
06 07 08 09 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30